Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — ATS Annual Meeting, Respiratory Innovation Summit 2026
9 slides from Kymera Therapeutics's conference presentation, May 2026
Slide 1: Revolutionizing Immunology with Oral Medicines
Revolutionizing Immunology with Oral Medicines Michael Feldman, MD, PhD Executive Medical Director Kymera Therapeutics ATS Annual Meeting, Respiratory Innovation Summit | May 2026
Slide 2: Targeted Protein Degradation: Achieving Biologics-like Activity with Oral Medicines
Targeted Protein Degradation: Achieving Biologics-like Activity with Oral Medicines Targeted Protein Degradation (TPD) Mechanism of Action Degraders Enable Continuous, Complete Pathway Blockade Harnessing the E3 Ubiquitin Proteasome System Superior to Traditional Small Molecule Inhibitors 1 2 3 4 Sm
Slide 3: STAT6: Highly Validated, Historically Undrugged Target for Type 2 Inflammatory Diseases
STAT6: Highly Validated, Historically Undrugged Target for the Treatment of Type 2 Inflammatory Diseases STAT6 KT-621 TRANSCRIPTION FACTOR FIRST-IN-CLASS • STAT6 is the specific ORAL STAT6 DEGRADER6 transcription factor in the Dupilumab IL-4 Dupilumab IL-4 IL-13 IL-4/IL-13 pathway1-3 IL-4Rα γc IL-4R
Slide 4: Achieved Deep STAT6 Degradation in Blood and Skin
KT-621 Achieved Deep STAT6 Degradation in Blood and Skin Degradation Maintained for 28 Days Across Both Dose Cohorts • KT-621 Phase 1b AD Study: Open-label, multicenter, single-arm study to evaluate the safety, tolerability, PK, PD, and clinical activity of oral KT-621 in adults with moderate-to-sev
Slide 5: Achieved Robust Reductions in Type 2 Inflammatory Biomarkers in Blood and Lungs (FeNO)
KT-621 Achieved Robust Reductions in Type 2 Inflammatory Biomarkers in Blood and Lungs (FeNO) Median % Change From Median % Change Median % Change Baseline in Eotaxin-3 from Baseline in FeNO from Baseline in FeNO (n=4)‡ Median % Change From Baseline in KT-621 100 mg QD (n=7)* 40 KT-621 100 mg QD (n=
Slide 6: Phase 1b Safety Summary
KT-621 Phase 1b Safety Summary • Well-tolerated with favorable safety at both 100 mg and 200 mg • No SAEs or Severe AEs • No dose-dependent pattern in the TEAEs • No related TEAEs or TEAEs leading to discontinuation • No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthra
Slide 7: Phase 1b BroADen Atopic Dermatitis Trial
KT-621 Phase 1b BroADen Atopic Dermatitis Trial First Evidence Demonstrating Clinical Activity and Safety of a STAT6-targeted Drug in Patients with Atopic Dermatitis • Deep STAT6 degradation in blood and lesional skin • Robust suppression of Type 2 inflammation • Robust impact on AD clinical endpoin
Slide 8: KT-621: BREADTH Phase 2b Trial
KT-621: BREADTH Phase 2b Trial Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Dose-ranging Design • Randomized, double-blind, placebo-controlled Key Trial Aim • ~264 patients • Daily dose for 12-weeks Establish clinical activity and safety in asthma to select Phase 3 Adult
Slide 9: Thank You
Thank You For more information, please visit our Booth #2501 or www.kymeratx.com ATS Annual Meeting | May 2026 9
Kymera Therapeutics — ATS Annual Meeting, Respiratory Innovation Summit 2026 on 6ix